

EUROPEAN PATENT OFFICE ALLOWS DERMAPORTATION PATENT

OBJ (ASX: OBJ) is pleased to advise that it has received notification from its patent attorney that the European patent application 04797047.0 protecting the Company's powered electromagnetic drug and cosmetic delivery technology "Dermaportation", has proceeded to Allowance. The US Patent Office granted this same patent Allowance for "Dermaportation" to OBJ in November of 2011.



The Notice of Allowance for the European Application will be followed by actual granting of the patent upon payment of applicable fees.

We are advised that formal granting of the patent normally occurs in approximately 3 to 6 months.

Dermaportation was the Company's first drug delivery technology and has recently been incorporated into the **e-Skin**[®] cosmetic device system which is the subject of commercial discussions with a global skin care company.


For more information:

Mr Glyn Denison	Director	Telephone	+618 9443 3011
		Email	info@obj.com.au
		Web	www.obj.com.au

For personal use only

OBJ Limited

leaders in magnetic micro-array drug delivery



About OBJ:

OBJ develops proprietary magnetic micro-array drug delivery and product enhancement technologies for the pharmaceutical, healthcare and consumer goods sectors.

OBJ partners companies in the design and development of next generation products using physical science rather than chemistry to provide new levels of product performance without the cost of reformulation or new ingredient approvals.

OBJ provides partnering and design expertise in:

- Transdermal Drug Delivery
- Cosmetic and Therapeutic Skincare
- Oral Health, Haircare and Deo-actives
- High Penetration Surface Care and Hygiene
- Fabric and Carpet Care

OBJ offers a portfolio of proprietary technologies and supports partners by providing IP-protected market exclusivity, expertise in magnetic array design, feasibility and efficacy and claims testing, engineering and production.

About OBJ's Technologies

OBJ has developed a platform of physical enhancement technologies based on low-cost magnetic micro-arrays that influence the movement and penetration of drugs, active ingredients and formulations at the molecular level.

Complex 3-D array and moving magnetic fields have the ability to repulse certain molecules to enhance diffusion and to alter the permeability of certain biological and non-biological targets.

OBJ is the first company to develop low cost micro-array film technology that utilises diamagnetic repulsion, induced permeation and energy redirection to offer a new way of managing the speed, depth of penetration and delivery of active ingredients in a wide range of pharmaceutical and consumer products.

For personal use only

ABN 72 056 482 636

284 Oxford Street, Leederville 6007 Perth, Western Australia
Telephone +61 8 9443 3011 Facsimile +61 8 9443 9960

www.obj.com.au